You are here

Microsatellite Instability (MSI) Assay

The Opportunity: 

Highly accurate and robust multiplexed sequencing assay for the stratification of tissue/tumours into microsatellite instability high (MSI-H) vs microsatellite instability suppressed (MSS) subtypes. This technology allows the stratification of cancer patients for immune checkpoint blockade therapy. Current sequencing and IHC based MSI analysis requires time consuming and costly expert analysis and is not designed to handle the volume of MSI analyses associated with new clinical guidelines (MHRA, FDA). Through the use of shorter markers than current tests and analysis using a proprietary algorithm, this assay offers the first reported automation-ready MSI testing for colorectal cancer and Lynch syndrome patients.

Downloadable PDF: